Durability is evidence.
Repeated survival matters when it reflects persistent demand, trusted execution and an organisation that has learned how not to break.
Private holding company
Lindy Compounding.
Time is not merely a holding period. It is part of the underwriting. We own a small number of public businesses where survival, learning and reinvestment can strengthen the enterprise with age.
Lindy × compounding
Lindy asks what becomes more durable with time. Compounding asks what can reinvest the result. We invest at the intersection.
Learning is an asset.
Process memory, customer trust and integration routines can become more valuable than the physical capacity visible on a balance sheet.
Concentration is a choice.
We prefer a short list of businesses we can follow deeply over broad ownership that substitutes diversification for understanding.
Disclosed portfolio
Three businesses.
Three compounding systems.
Each position is framed around the mechanism that can compound, then tested against the evidence that could weaken or invalidate it. Current prices, quantities and portfolio values are not published.
01 / 03
NSE: LAURUSLABS
Laurus Labs
The manufacturing layer beneath faster drug discovery.
AI can accelerate the discovery of viable molecules faster than regulated manufacturing can scale. Laurus is a founder-led molecular manufacturing platform spanning small molecules, biologics, fermentation and advanced chemistry. Its durable asset is not capacity alone, but customer trust, regulatory credibility, process memory and a capability stack that can make each successful programme increase the odds of the next.
Compounding mechanism
Repeat programmes, institutional learning and regulatory trust can raise switching costs over time.
What we watch
Customer depth, cash conversion and whether expansion strengthens focus rather than diffusing it.
- Entry date
- 08 Jul 2025
- Entry price
- ₹770.57
02 / 03
NSE: SOLARA
Solara Active Pharma
A turnaround into a higher-value chemistry platform.
The thesis is a shift away from volume-led, ibuprofen-heavy API production toward a pull-driven, higher-margin, multi-chemistry platform. A repaired balance sheet, the Vizag facility and capabilities in CRAMS, therapeutic polymers, high-potency chemistry and peptide or oligonucleotide building blocks create meaningful operating leverage. The opportunity is real, but execution remains the proof.
Compounding mechanism
Mix improvement, higher utilisation and sticky customer programmes can expand both margins and relevance.
What we watch
Vizag ramp-up, working-capital discipline, cash conversion and management stability.
- Entry date
- 28 Apr 2026
- Entry price
- ₹482.93
03 / 03
NSE: ENTERO
Entero Healthcare
Consolidating India’s fragmented healthcare distribution layer.
Entero acquires regional distributors, retains their local relationships, integrates them onto proprietary systems and expands into higher-margin categories. The compounding engine is acquisition discipline plus integration learning. Scale creates value only when local knowledge survives, technology improves decisions and working-capital economics become stronger with each cohort.
Compounding mechanism
Better sourcing, denser distribution, faster integration and a growing operating playbook.
What we watch
Organic growth, working-capital normalisation and retention of acquired relationships and operators.
- Entry date
- 24 Jun 2026
- Entry price
- ₹1,101.13
Entry dates are the portfolio's recorded entry dates. Each benchmark sleeve uses the same date and original capital weight as its corresponding holding.
Capital-matched comparison
Performance, without publishing the balance sheet.
Snapshot
Lindy portfolioMatched entries
+40.96%
Nifty 50Price index
Live feed
Nifty 500Price index
Live feed
Nifty PharmaPrice index
Live feed
Capital-matched return
Each new position and each benchmark sleeve enters on the same entry date. The chart therefore compares identical deployment timing rather than using one arbitrary inception date.
Live chart loads after market data connects
Deploy the complete Cloudflare package to load live benchmark history.
Lindy portfolio
Nifty 50
Nifty 500
Nifty Pharma
A fair comparison for staggered entries.
Matched capital. Each holding is treated as a separate sleeve. On its entry date, the same capital weight is notionally placed into every benchmark. The sleeves are then aggregated using original cost weights.
Published return only. The page stores normalised weights, not quantities or portfolio values. Returns are price returns and exclude dividends, taxes, fees and later transactions unless the configuration is updated.
The Lindy franchise
Lindy Compounding is the capital arm of a broader long-duration project.
Founded and run by Abhay Aditya Jain, Lindy Compounding applies the same concern with durable identity and accumulated trust that sits behind Lindy Panels, but to the ownership of public businesses.
The objective is not activity. It is to find a limited number of systems where time can improve the underlying economics, then remain patient while the evidence develops.